JP2017509632A5 - - Google Patents

Download PDF

Info

Publication number
JP2017509632A5
JP2017509632A5 JP2016557218A JP2016557218A JP2017509632A5 JP 2017509632 A5 JP2017509632 A5 JP 2017509632A5 JP 2016557218 A JP2016557218 A JP 2016557218A JP 2016557218 A JP2016557218 A JP 2016557218A JP 2017509632 A5 JP2017509632 A5 JP 2017509632A5
Authority
JP
Japan
Prior art keywords
nucleic acid
raav
seq
acid encoding
mir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016557218A
Other languages
English (en)
Japanese (ja)
Other versions
JP6669664B2 (ja
JP2017509632A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/021896 external-priority patent/WO2015143418A2/en
Publication of JP2017509632A publication Critical patent/JP2017509632A/ja
Publication of JP2017509632A5 publication Critical patent/JP2017509632A5/ja
Application granted granted Critical
Publication of JP6669664B2 publication Critical patent/JP6669664B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016557218A 2014-03-21 2015-03-20 網膜色素変性症のための遺伝子治療 Active JP6669664B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461969027P 2014-03-21 2014-03-21
US61/969,027 2014-03-21
PCT/US2015/021896 WO2015143418A2 (en) 2014-03-21 2015-03-20 Gene therapy for retinitis pigmentosa

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019224202A Division JP7048563B2 (ja) 2014-03-21 2019-12-12 網膜色素変性症のための遺伝子治療

Publications (3)

Publication Number Publication Date
JP2017509632A JP2017509632A (ja) 2017-04-06
JP2017509632A5 true JP2017509632A5 (enExample) 2018-04-26
JP6669664B2 JP6669664B2 (ja) 2020-03-18

Family

ID=52829343

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016557218A Active JP6669664B2 (ja) 2014-03-21 2015-03-20 網膜色素変性症のための遺伝子治療
JP2019224202A Active JP7048563B2 (ja) 2014-03-21 2019-12-12 網膜色素変性症のための遺伝子治療
JP2022046280A Active JP7534348B2 (ja) 2014-03-21 2022-03-23 網膜色素変性症のための遺伝子治療

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019224202A Active JP7048563B2 (ja) 2014-03-21 2019-12-12 網膜色素変性症のための遺伝子治療
JP2022046280A Active JP7534348B2 (ja) 2014-03-21 2022-03-23 網膜色素変性症のための遺伝子治療

Country Status (36)

Country Link
US (3) US10383953B2 (enExample)
EP (3) EP3119437B1 (enExample)
JP (3) JP6669664B2 (enExample)
KR (3) KR20250172735A (enExample)
CN (2) CN115252823A (enExample)
AR (1) AR099837A1 (enExample)
AU (3) AU2015230942B2 (enExample)
CA (2) CA3254798A1 (enExample)
CL (1) CL2016002333A1 (enExample)
CR (1) CR20160480A (enExample)
DK (2) DK3119437T3 (enExample)
DO (1) DOP2016000237A (enExample)
EA (1) EA201691891A1 (enExample)
EC (1) ECSP16083000A (enExample)
ES (2) ES2957840T3 (enExample)
FI (1) FI3628334T3 (enExample)
HR (2) HRP20192141T1 (enExample)
HU (2) HUE063460T2 (enExample)
IL (3) IL247543B (enExample)
LT (2) LT3119437T (enExample)
MA (1) MA39390B2 (enExample)
MX (2) MX376190B (enExample)
MY (2) MY190726A (enExample)
NZ (1) NZ724622A (enExample)
PE (1) PE20161252A1 (enExample)
PH (1) PH12016501684B1 (enExample)
PL (2) PL3628334T3 (enExample)
PT (2) PT3119437T (enExample)
RS (2) RS59634B1 (enExample)
SG (3) SG10201808218YA (enExample)
SI (2) SI3628334T1 (enExample)
TW (2) TWI706789B (enExample)
UA (1) UA120050C2 (enExample)
UY (1) UY36044A (enExample)
WO (1) WO2015143418A2 (enExample)
ZA (1) ZA201605924B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201808218YA (en) 2014-03-21 2018-10-30 Genzyme Corp Gene therapy for retinitis pigmentosa
EP3256588A2 (en) 2015-02-10 2017-12-20 Genzyme Corporation VARIANT RNAi
CN108474001B (zh) * 2015-12-03 2022-04-08 弗里德里克·米谢尔生物医学研究所 SynP160,用于基因在视杆光感受器中特异性表达的启动子
ES2886664T3 (es) 2015-12-03 2021-12-20 Friedrich Miescher Institute For Biomedical Res SynP162, un promotor para la expresión específica de genes en fotorreceptores de bastón
KR102312253B1 (ko) * 2015-12-04 2021-10-15 쏘흐본느 유니베흐시테 프로모터 및 이의 용도
CN109154002B (zh) * 2016-03-01 2022-08-30 佛罗里达大学研究基金会有限公司 用于治疗显性视网膜色素变性的aav载体
JP2019520391A (ja) * 2016-07-05 2019-07-18 ザ・ジョンズ・ホプキンス・ユニバーシティー 網膜変性を処置するためのcrispr/cas9ベースの組成物および方法
CA3056211A1 (en) * 2017-03-21 2018-09-27 Stylianos MICHALAKIS Gene therapy for the treatment of cngb1-linked retinitis pigmentosa
UY37897A (es) * 2017-09-22 2019-04-30 Genzyme Corp ARNi VARIANTE
WO2019067766A1 (en) * 2017-09-27 2019-04-04 Sigilon Therapeutics, Inc. METHODS, COMPOSITIONS AND IMPLANTABLE ELEMENTS COMPRISING ACTIVE CELLS
CN107961380B (zh) * 2017-11-23 2020-05-05 清华大学 试剂在制备药物中的用途、筛选药物的方法以及药物组合物
WO2019169245A1 (en) 2018-03-02 2019-09-06 Sigilon Therapeutics, Inc. Biocompatible hydrogel capsules and process for preparing same
EP3768327A4 (en) * 2018-03-23 2022-04-13 The Trustees of Columbia University in the City of New York GENE EDITING FOR AUTOSOMAL DOMINANT DISEASES
KR20210005608A (ko) 2018-04-04 2021-01-14 시질론 테라퓨틱스, 인크. 이식 가능한 입자 및 관련 방법
CN118480544A (zh) 2018-06-01 2024-08-13 佛罗里达大学研究基金会有限公司 用于治疗显性视网膜色素变性的组合物和方法
GB201817469D0 (en) * 2018-10-26 2018-12-12 Univ Oxford Innovation Ltd Gene therapy for retinal disease
CN111518813B (zh) * 2019-02-03 2023-04-28 武汉纽福斯生物科技有限公司 视紫红质的编码序列、其表达载体构建及其应用
SG11202109554XA (en) * 2019-03-04 2021-09-29 Univ Pennsylvania Neuroprotective gene therapy targeting the akt pathway
SG11202109736RA (en) * 2019-03-21 2021-10-28 Ptc Therapeutics Inc Vector and method for treating angelman syndrome
EP4013414A4 (en) * 2019-08-15 2023-09-27 The Children's Hospital of Philadelphia COMBINED INTRON-DERIVED MIRNA AND TRANSGENE THERAPY FOR THE TREATMENT OF SCA1
WO2021142447A1 (en) * 2020-01-10 2021-07-15 Solid Biosciences Inc. Viral vector for combination therapy
BR112022014852A2 (pt) * 2020-01-29 2022-10-11 Genzyme Corp Proteínas modificadas do capsídeo viral adenoassociado para terapia gênica ocular e métodos de uso das mesmas
EP4071247A4 (en) * 2020-07-24 2023-08-23 Rznomics Inc. TRANSSPLICING OF RIBOZYME SPECIFIC TO RHODOPSIN TRANSCRIPTOME AND ITS USE
CN116568338A (zh) * 2020-07-29 2023-08-08 佛罗里达州大学研究基金会 改进的aav介导的x连锁视网膜劈裂症治疗
EP4323390A1 (en) * 2021-04-16 2024-02-21 Regeneron Pharmaceuticals, Inc. Treatment of x-linked juvenile retinoschisis
TWI832531B (zh) * 2022-11-02 2024-02-11 慈濟學校財團法人慈濟大學 Rip1抑制劑或mlkl抑制劑用於治療或預防遺傳性視網膜失養症的用途
CN117625619B (zh) * 2023-12-05 2024-11-12 云舟生物科技(广州)股份有限公司 核酸分子及其作为特异启动子的应用
CN120230798A (zh) * 2023-12-29 2025-07-01 上海朗昇生物科技有限公司 用于视网膜基因递送的重组腺相关病毒载体及其应用

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262529A (en) * 1990-01-24 1993-11-16 President And Fellows Of Harvard College Diagnosis of hereditary retinal degenerative diseases
US5985583A (en) * 1992-06-23 1999-11-16 Mount Sinai School Of Medicine Of The City University Of New York Cloning and expression of gonadotropin-releasing hormone receptor
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6995006B2 (en) 1997-09-05 2006-02-07 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
JP4860886B2 (ja) 2000-06-01 2012-01-25 ユニヴァーシティ・オヴ・ノース・キャロライナ・アト・チャペル・ヒル 二本鎖パルボウイルスベクター
BR122016004546B8 (pt) 2001-11-13 2021-07-27 Univ Pennsylvania vírus adenoassociado recombinante, método de geração do referido vírus e composição compreendendo o referido vírus
EP1486567A1 (en) 2003-06-11 2004-12-15 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Improved adeno-associated virus (AAV) vector for gene therapy
EP1717317A4 (en) * 2004-01-22 2009-02-11 Dnavec Research Inc METHOD OF GENERATING VIRAL NEGATIVE STRAND RNA VECTORS USING A HYBRID PROMOTER COMPRISING THE CYTOMEGALOVIRUS ENHANCER AND THE BETA ACTIN PROMOTER FROM CHICKEN
US7765583B2 (en) 2005-02-28 2010-07-27 France Telecom System and method for managing virtual user domains
WO2006119432A2 (en) 2005-04-29 2006-11-09 The Government Of The U.S.A., As Rep. By The Sec., Dept. Of Health & Human Services Isolation, cloning and characterization of new adeno-associated virus (aav) serotypes
EP2007795B1 (en) 2006-03-30 2016-11-16 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid proteins
CA2683469C (en) 2007-04-12 2019-11-26 The Provost, Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Genetic suppression and replacement
US20090214478A1 (en) * 2008-02-21 2009-08-27 Alberto Auricchio Method of treating ocular diseases by gene therapy
US9217155B2 (en) * 2008-05-28 2015-12-22 University Of Massachusetts Isolation of novel AAV'S and uses thereof
WO2010138263A2 (en) 2009-05-28 2010-12-02 University Of Massachusetts Novel aav 's and uses thereof
US9078914B2 (en) 2009-09-10 2015-07-14 Velin-Pharma A/S Method for the preparation of micro-RNA and its therapeutic application
PT2529020T (pt) 2010-01-28 2018-07-30 Childrens Hospital Philadelphia Plataforma de fabrico escalável para purificação de vetor viral e vetores virais assim purificados para utilização na terapia génica
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
US10738326B2 (en) 2010-10-27 2020-08-11 Jichi Medical University Adeno-associated virus vector for gene transfer to nervous system cells
BR112013020734A2 (pt) 2011-02-17 2017-06-13 Univ Pennsylvania composições e métodos para alterar a especificidade do tecido e aprimorar a transferência gênica mediada por aav9
JP5884152B2 (ja) 2011-07-29 2016-03-15 シャープ株式会社 基地局、端末、通信システムおよび通信方法
ITRM20110685A1 (it) * 2011-12-23 2013-06-24 Internat Ct For Genetic En Gineering And Microrna per la rigenerazione cardiaca attraverso l induzione della proliferazione dei miociti cardiaci
MX367100B (es) * 2012-02-17 2019-08-05 The Children´S Hospital Of Philadelphia Composiciones del vector aav y metodos para su transferencia genetica a celulas, organos y tejidos.
AU2013243955B2 (en) * 2012-04-02 2018-02-22 Modernatx, Inc. Modified polynucleotides for the production of oncology-related proteins and peptides
US9127274B2 (en) * 2012-04-26 2015-09-08 Alnylam Pharmaceuticals, Inc. Serpinc1 iRNA compositions and methods of use thereof
NZ714353A (en) * 2012-05-25 2017-05-26 Univ California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
JP6199965B2 (ja) 2012-07-11 2017-09-20 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア Rpgrx連鎖性網膜変性のaav媒介型遺伝子治療
CA2889020A1 (en) * 2012-10-23 2014-05-01 Cornell University Treatment of metastatic breast cancer
US9884125B2 (en) 2013-10-04 2018-02-06 Merck Sharp & Dohme Corp. Glucose-responsive insulin conjugates
SG10201808218YA (en) * 2014-03-21 2018-10-30 Genzyme Corp Gene therapy for retinitis pigmentosa

Similar Documents

Publication Publication Date Title
JP2017509632A5 (enExample)
HRP20192141T1 (hr) Genska terapija za retinitis pigmentosa
JP2024009857A5 (enExample)
JP6994018B2 (ja) 新規アデノ随伴ウイルスキャプシドタンパク質
JP2018522529A5 (enExample)
JP2021106619A5 (enExample)
JP2018510648A5 (enExample)
JP2019116492A5 (enExample)
JP2020522269A5 (enExample)
JP2018108113A5 (enExample)
JP2020519284A5 (enExample)
AU2019250249A1 (en) Promoters, expression cassettes, vectors, kits, and methods for the treatment of achromatopsia and other diseases
IL292999A (en) Compositions and methods of treating amyotrophic lateral sclerosis (als)
JP2020500541A5 (enExample)
JP2017535266A5 (enExample)
RU2017115477A (ru) Полинуклеотиды aadc для лечения болезни паркинсона
JP2017529395A5 (enExample)
IL292264B2 (en) aav transfer cassette
JP2020519294A5 (enExample)
JPWO2021067448A5 (enExample)
JPWO2020214609A5 (enExample)
JPWO2020168222A5 (enExample)
JP2019500034A5 (enExample)
JPWO2020186207A5 (enExample)
JP2023059858A5 (enExample)